Chewy vs. Coupang: Steady vs. Fluctuating Quarterly Revenue Trends

Across the eight reported quarters, Coupang revenue exceeded Chewy’s in every period; in Q2 2026 it was $8.9B versus Chewy’s $3.3B. The article says Chewy’s revenue was comparatively steady while Coupang’s fluctuated, and favors Chewy for its expansion potential and lower P/S ratio (0.6 versus 0.8), despite neither company delivering compelling revenue growth. Coupang is described as currently unprofitable and faces a South Korean regulatory investigation over pricing and supplier policies.

Analysis

The headline comparison is a weak basis for choosing between these stocks: reported revenue scale and its quarter-to-quarter pattern do not establish relative growth quality, unit economics, or valuation. Chewy’s potential upside depends on whether clinics and Canada add durable customer spend without diluting returns through build-out costs; the key evidence is clinic utilization, contribution economics, and customer retention—not clinic count. The supplement recall is a supplier-level event, not evidence of a company-wide product problem, but broader recurrence could raise trust and sourcing risk.

For Coupang, Taiwan expansion offers a growth option, but customer acquisition and delivery density determine whether added coverage creates economic value. A Korean regulatory dispute could be more consequential than a single quarter of sales softness if remedies constrain pricing, supplier terms, or platform economics. It could also encourage merchants to diversify channels, benefiting competing marketplaces, including Sea Limited in Taiwan, though the company’s broader business mix makes it an imperfect hedge.

Near term, avoid treating the revenue comparison or the stated P/S multiples as a standalone catalyst. Over 1–3 months, monitor regulatory findings and company disclosures on Taiwan economics; over 6–18 months, test whether Chewy’s clinic expansion produces measurable returns and whether Coupang’s international growth offsets any home-market friction. The contrarian risk is that the apparent Chewy valuation advantage reflects lower expected growth or investment returns, while Coupang’s revenue fluctuations may partly reflect reporting mix rather than weakening demand. Falsify the cautious CPNG view if the regulatory process resolves without material operating restrictions and international growth sustains improving profitability; falsify the CHWY expansion thesis if clinic economics or customer metrics fail to improve.

Key Decisions for Investors

• No immediate trade on this revenue comparison alone. Do not infer a growth or valuation edge from differently scoped businesses, quarter patterns, or P/S multiples without checking comparable-period growth, margins, cash generation, and valuation assumptions.
• Treat CHWY as a catalyst watch: revisit a long only when filings show clinic utilization or returns improving alongside customer retention and operating economics. Reassess if expansion costs rise without evidence of incremental spend or retention.
• Keep CPNG regulatory exposure on the event calendar; verify the investigation’s scope, potential remedies, and any changes to supplier or pricing policies before positioning. A material restriction or merchant-channel shift would strengthen the downside case; a benign resolution would weaken it.
• Track Taiwan customer acquisition, delivery density, and profitability disclosures for CPNG, and competitive responses from Sea Limited. Expansion in coverage without improving economics is not sufficient evidence of value creation.